# W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne

> **NCT01132443** · PHASE1 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 72 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,

## Key facts

- **NCT ID:** NCT01132443
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-06
- **Primary completion:** 2010-06-12
- **Final completion:** 2010-06-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132443, "W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01132443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*